Head-To-Head Review: Mirum Pharmaceuticals (NASDAQ:MIRM) & BioAtla (NASDAQ:BCAB)

BioAtla (NASDAQ:BCAB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Profitability

This table compares BioAtla and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	-1,177.18%	-200.66%
Mirum Pharmaceuticals	-8.78%	-16.47%	-5.77%

Volatility and Risk

BioAtla has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for BioAtla and Mirum Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1	3	0	0	1.75
Mirum Pharmaceuticals	1	0	12	2	3.00

Mirum Pharmaceuticals has a consensus price target of $95.75, indicating a potential upside of 47.31%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than BioAtla.

Valuation and Earnings

This table compares BioAtla and Mirum Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$11.00 million	4.41	-$69.78 million	($1.15)	-0.72
Mirum Pharmaceuticals	$336.89 million	9.92	-$87.94 million	($0.86)	-75.58

BioAtla has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.2% of BioAtla shares are owned by institutional investors. 11.2% of BioAtla shares are owned by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats BioAtla on 10 of the 15 factors compared between the two stocks.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.